Drugs / RH324
last change Feb 2026 re-read 3 minutes ago

RH324

Investigated by
ReHeva Biosciences,Inc.

Trials 1

2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05580172 Jun 2022 → Jun 2024 — ReHeva Biosciences,Inc. Unknown Met primary

Press releases naming this drug 1 release

DateIssuerRelease
2022-05-25 ReHeva Biosciences,Inc. REHEVA BIOSCIENCES ANNOUNCES FIRST PATIENT ENROLLED IN RH324 PHASE I SAFETY TRIAL rehevabiosciences.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as RH324 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05580172 ↗
Known as Withania somnifera Leaf Extract “Phase 1 Trial of Withania somnifera Leaf Extract (RH324) in Advanced Non-Small Cell Lung Cancer Including [(18)F]FDG PET/CT as a Short-Term Metabolic Biomarker to Assess...” PMID 41685666 ↗ Feb 2026
Route Oral “A phase 1 open label dose ranging study of oral RH324 in advanced non-small cell lung cancer (NSCLC) was conducted.” PMID 41685666 ↗ Feb 2026